These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33475881)

  • 1. Who Will Benefit? Using Radiomics to Predict Response to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases.
    Hewitt DB; Pawlik TM; Cloyd JM
    Ann Surg Oncol; 2021 Jun; 28(6):2931-2933. PubMed ID: 33475881
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflection: Radiomics-Based Prediction for the Responder to First-Line Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastasis.
    Nakanishi R; Oki E; Hasuda H; Sano E; Miyashita Y; Sakai A; Koga N; Kuriyama N; Nonaka K; Fujimoto Y; Jogo T; Hokonohara K; Hu Q; Hisamatsu Y; Ando K; Kimura Y; Yoshizumi T; Mori M
    Ann Surg Oncol; 2021 Jun; 28(6):2986-2987. PubMed ID: 33725205
    [No Abstract]   [Full Text] [Related]  

  • 3. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
    Larsen FO; Jensen BV; Nørgaard HH; Hermann HK; Larsen PN; Markussen A; Hogdall E; Nielsen D
    Oncology; 2019; 96(6):299-308. PubMed ID: 30999314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting response to neoadjuvant chemotherapy for colorectal liver metastasis using deep learning on prechemotherapy cross-sectional imaging.
    Davis JMK; Niazi MKK; Ricker AB; Tavolara TE; Robinson JN; Annanurov B; Smith K; Mantha R; Hwang J; Shrestha R; Iannitti DA; Martinie JB; Baker EH; Gurcan MN; Vrochides D
    J Surg Oncol; 2024 Jul; 130(1):93-101. PubMed ID: 38712939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
    Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
    Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.
    Khin NY; De Silva M; Clarke S; Pavlakis N; Rogan CM; Ho-Shon K; Lane RJ
    Ann Surg Oncol; 2022 Jun; 29(6):3387-3389. PubMed ID: 35147822
    [No Abstract]   [Full Text] [Related]  

  • 7. Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy.
    Nakanishi R; Oki E; Hasuda H; Sano E; Miyashita Y; Sakai A; Koga N; Kuriyama N; Nonaka K; Fujimoto Y; Jogo T; Hokonohara K; Hu Q; Hisamatsu Y; Ando K; Kimura Y; Yoshizumi T; Mori M
    Ann Surg Oncol; 2021 Jun; 28(6):2975-2985. PubMed ID: 33454878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of a Phase I/II Trial of Hepatic Arterial Infusion of Oxaliplatin Combined with Intravenous 5-Fluorouracil and l-Leucovorin in Patients with Unresectable Liver Metastases from Colorectal Cancer After Systemic Chemotherapy Failure.
    Sato Y; Inaba Y; Ura T; Nishiofuku H; Yamaura H; Kato M; Takahari D; Tanaka T; Muro K
    J Gastrointest Cancer; 2018 Jun; 49(2):132-137. PubMed ID: 28058527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
    Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
    Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Lévi FA; Boige V; Hebbar M; Smith D; Lepère C; Focan C; Karaboué A; Guimbaud R; Carvalho C; Tumolo S; Innominato P; Ajavon Y; Truant S; Castaing D; De Baere T; Kunstlinger F; Bouchahda M; Afshar M; Rougier P; Adam R; Ducreux M;
    Ann Oncol; 2016 Feb; 27(2):267-74. PubMed ID: 26578731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of chemotherapy with S-1 and oxaliplatin (SOX) in combination with molecular-targeting agents on colorectal liver metastases.
    Watanabe K; Kawahara H; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 Sep; 33(9):3941-6. PubMed ID: 24023332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
    Chikatani K; Ishibashi K; Tajima Y; Hatano S; Amano K; Ishiguro T; Kuwabara K; Sobajima J; Ohsawa T; Okada N; Kumamoto K; Haga N; Iwama T; Ishida H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2211-3. PubMed ID: 22202333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
    Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
    J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
    J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced image analytics predicting clinical outcomes in patients with colorectal liver metastases: A systematic review of the literature.
    Wesdorp NJ; van Goor VJ; Kemna R; Jansma EP; van Waesberghe JHTM; Swijnenburg RJ; Punt CJA; Huiskens J; Kazemier G
    Surg Oncol; 2021 Sep; 38():101578. PubMed ID: 33866191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second line therapies move to the forefront in colorectal cancer.
    Miller M
    J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
    [No Abstract]   [Full Text] [Related]  

  • 20. Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.
    Irving GR; Iwuji CO; Morgan B; Berry DP; Steward WP; Thomas A; Brown K; Howells LM
    Trials; 2015 Mar; 16():110. PubMed ID: 25872567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.